SHL Medical AG

SHL Medical AG has been granted 344 US utility patents between 2019 and 2025, placing SHL Medical AG at rank #1,237 across all assignees tracked by PlainPatent. This portfolio spans 39 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.4 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, SHL Medical AG is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 57.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 290 grants, compared with 54 in the 2015–2019 window — a +437% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. SHL Medical AG's 15.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 39 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark SHL Medical AG against peers pursuing similar technology classes.